These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39183405)

  • 1. A disulfidptosis-associated long noncoding RNA signature to predict low-grade glioma classification, prognosis, tumor microenvironment, and therapy regimens: Observational study.
    Qin X; Chen Z; Wu L; Ding R
    Medicine (Baltimore); 2024 Aug; 103(34):e39316. PubMed ID: 39183405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
    Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
    Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
    Lin WW; Ou GY; Zhao WJ
    J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
    Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
    Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cuproptosis-based prognostic model for predicting survival in low-grade glioma.
    Zhao Z; Ma Y; Liu Y; Chen Z; Zheng J
    Aging (Albany NY); 2024 May; 16(10):8697-8716. PubMed ID: 38738989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma.
    Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B
    Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
    Xing F; Qin Y; Xu J; Wang W; Zhang B
    Mol Biotechnol; 2024 Sep; 66(9):2396-2414. PubMed ID: 37733182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-related gene-located DNA methylation in lower-grade glioma: Prognosis and tumor microenvironment.
    Zhu L; Yuan F; Wang X; Zhu R; Guo W
    Cancer Biomark; 2024; 40(2):185-198. PubMed ID: 38578883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
    Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
    Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A disulfidptosis-related lncRNA signature for analyzing tumor microenvironment and clinical prognosis in hepatocellular carcinoma.
    Zheng H; Cheng J; Zhuang Z; Li D; Yang J; Yuan F; Fan X; Liu X
    Front Immunol; 2024; 15():1412277. PubMed ID: 39434887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A disulfidptosis-related classification and risk signature identifies immunotherapy biomarkers and predicts prognosis in gastric cancer: An observational study.
    Chen R; Jiang L
    Medicine (Baltimore); 2024 May; 103(22):e38398. PubMed ID: 39259065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a risk score model based on glycosylation-related genes in the prognosis and treatment of patients with low-grade glioma.
    Zou B; Li M; Zhang J; Gao Y; Huo X; Li J; Fan Y; Guo Y; Liu X
    Front Immunol; 2024; 15():1467858. PubMed ID: 39445005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
    Chen J; Li Y; Han X; Pan Y; Qian X
    Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
    Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
    Front Immunol; 2022; 13():982033. PubMed ID: 36052073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.